[go: up one dir, main page]

ES2114471A1 - Nuevos compuestos de paroxetina y procedimiento para su preparacion. - Google Patents

Nuevos compuestos de paroxetina y procedimiento para su preparacion.

Info

Publication number
ES2114471A1
ES2114471A1 ES09600262A ES9600262A ES2114471A1 ES 2114471 A1 ES2114471 A1 ES 2114471A1 ES 09600262 A ES09600262 A ES 09600262A ES 9600262 A ES9600262 A ES 9600262A ES 2114471 A1 ES2114471 A1 ES 2114471A1
Authority
ES
Spain
Prior art keywords
preparation
paroxetine
solvent
hydrochloride anhydrate
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES09600262A
Other languages
English (en)
Other versions
ES2114471B1 (es
Inventor
Victor Witold Jacewicz
Neal Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27267578&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2114471(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9502297.6A external-priority patent/GB9502297D0/en
Priority claimed from GBGB9503112.6A external-priority patent/GB9503112D0/en
Priority claimed from GBGB9509807.5A external-priority patent/GB9509807D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Priority to ES9900042A priority Critical patent/ES2149726B1/es
Publication of ES2114471A1 publication Critical patent/ES2114471A1/es
Application granted granted Critical
Publication of ES2114471B1 publication Critical patent/ES2114471B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

NUEVOS COMPUESTOS DE PAROXETINA Y PROCEDIMIENTO PARA SU PREPARACION. SE DESCRIBEN EN CONCRETO HIDROCLORURO DE PAROXETINA ANHIDRO SUSTANCIALMENTE EXENTO DE PROPAN-2-OL COMBINADO, VARIAS FORMAS DEL ANTERIOR, PROCEDIMIENTOS PARA PREPARAR EL ANTERIOR, NUEVOS COMPUESTOS INTERMEDIOS UTILES EN LA PREPARACION DEL ANTERIOR Y METODOS DE TRATAMIENTO Y/O PREVENCION DE CIERTAS ENFERMEDADES POR ADMINISTRACION DE LOS COMPUESTOS DE LA INVENCION A UN PACIENTE QUE SE ENCUENTRA EN NECESIDAD DE ELLOS. EL PROCEDIMIENTO SE CARACTERIZA PORQUE SE CRISTALIZA EL HIDROCLURO DE PAROXETINA EN UN DISOLVENTE ORGANICO, Y A CONTINUACION SE DESPLAZA EL DISOLVENTE O SE EXPULSA EL DISOLVENTE. (FIGURA 1).
ES09600262A 1995-02-06 1996-02-05 Nuevos compuestos de paroxetina y procedimiento para su preparacion. Expired - Fee Related ES2114471B1 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES9900042A ES2149726B1 (es) 1995-02-06 1996-02-05 Nuevos compuestos de paroxetina.

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9502297.6A GB9502297D0 (en) 1995-02-06 1995-02-06 Novel compound
GBGB9503112.6A GB9503112D0 (en) 1995-02-17 1995-02-17 Novel compound
GBGB9509807.5A GB9509807D0 (en) 1995-05-15 1995-05-15 Novel compounds

Publications (2)

Publication Number Publication Date
ES2114471A1 true ES2114471A1 (es) 1998-05-16
ES2114471B1 ES2114471B1 (es) 1999-08-16

Family

ID=27267578

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09600262A Expired - Fee Related ES2114471B1 (es) 1995-02-06 1996-02-05 Nuevos compuestos de paroxetina y procedimiento para su preparacion.

Country Status (47)

Country Link
EP (3) EP0808314B1 (es)
JP (2) JP2915338B2 (es)
KR (1) KR100289885B1 (es)
CN (3) CN1289496C (es)
AR (2) AR001982A1 (es)
AT (1) AT407528B (es)
AU (2) AU701518C (es)
BE (1) BE1009112A3 (es)
BG (1) BG62967B1 (es)
BR (1) BR9600534A (es)
CA (3) CA2211522C (es)
CH (3) CH688353A5 (es)
CZ (1) CZ297171B6 (es)
DE (3) DE69621777T2 (es)
DK (2) DK11996A (es)
DZ (1) DZ1989A1 (es)
ES (1) ES2114471B1 (es)
FI (3) FI111544B (es)
FR (1) FR2730232B1 (es)
GR (1) GR1002466B (es)
HK (1) HK59397A (es)
HU (1) HUP9600255A1 (es)
IE (1) IE80500B1 (es)
IL (1) IL117035A (es)
IT (1) IT1289532B1 (es)
LU (1) LU88711A1 (es)
LV (1) LV11618B (es)
MA (1) MA23802A1 (es)
MC (1) MC2411A1 (es)
MX (1) MX9600484A (es)
MY (1) MY132529A (es)
NL (1) NL1002248C2 (es)
NO (3) NO301009B1 (es)
NZ (1) NZ280943A (es)
OA (1) OA10261A (es)
PL (1) PL189247B1 (es)
PT (1) PT101827B (es)
RO (1) RO112426B1 (es)
RU (1) RU2125052C1 (es)
SE (1) SE521084C2 (es)
SG (1) SG43787A1 (es)
SI (2) SI9600036B (es)
SK (1) SK283608B6 (es)
TR (1) TR199600096A2 (es)
TW (1) TW503238B (es)
UA (1) UA49796C2 (es)
WO (1) WO1996024595A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3882224B2 (ja) 1996-05-31 2007-02-14 旭硝子株式会社 パロキセチンの製造方法
EP1394160A1 (en) * 1996-06-13 2004-03-03 SUMIKA FINE CHEMICALS Co., Ltd. Process for preparing crystalline paroxetin hydrochloride
JP2000514653A (ja) * 1996-07-15 2000-11-07 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 立体特異的分割のためのエステラーゼのスクリーニングおよびその使用
US6638948B1 (en) 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US5672612A (en) * 1996-09-09 1997-09-30 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
CA2193939C (en) * 1996-12-24 2002-02-12 K.S. Keshava Murthy Useful form of anhydrous paroxetine hydrochloride
SK283394B6 (sk) * 1997-06-10 2003-07-01 Synthon B. V. Zlúčeniny 4-fenylpiperidínu a jej farmaceuticky prijateľné soli, spôsob ich prípravy, liečivo s ich obsahom a ich použitie
PT903345E (pt) * 1997-08-08 2001-01-31 Aventis Pharma Gmbh Forma cristalina de n-(4-trifluorometilfenil)-5-metil-isoxazolo-4-carboxamida
GB9726907D0 (en) * 1997-12-19 1998-02-18 Smithkline Beecham Plc Novel compounds
CN1300286A (zh) * 1998-03-16 2001-06-20 史密丝克莱恩比彻姆有限公司 帕罗西丁的晶形
US6699882B2 (en) 1998-03-24 2004-03-02 Smithkline Beecham P.L.C. Paroxetine compositions
GB9806312D0 (en) * 1998-03-24 1998-05-20 Smithkline Beecham Plc Novel formulations
AU2003200534B2 (en) * 1998-03-24 2004-12-02 Smithkline Beecham Plc Paroxetine compositions
JP3796351B2 (ja) * 1998-04-13 2006-07-12 住友化学株式会社 パロキセチン塩酸塩無水和物の乾燥方法
GB9812941D0 (en) * 1998-06-16 1998-08-12 Smithkline Beecham Plc Method of treatment
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
ES2138937B1 (es) 1998-07-07 2000-10-01 Medichem Sa Polimorfo de maleato de paroxetina y formulaciones farmaceuticas que lo contienen.
HUP0105466A3 (en) * 1998-08-07 2002-11-28 Smithkline Beecham Plc Process for the preparation of a non-crystalline anhydrate form of paroxetine hydrochloride and pharmaceutical compositions containing them
GB9824298D0 (en) * 1998-11-05 1998-12-30 Smithkline Beecham Plc Novel process
GB9826176D0 (en) * 1998-11-28 1999-01-20 Smithkline Beecham Plc Novel process
GB9826175D0 (en) * 1998-11-28 1999-01-20 Smithkline Beecham Plc Novel process
DE69913377T2 (de) * 1998-11-30 2004-12-30 Smithkline Beecham P.L.C., Brentford Gemischte Paroxetin-Propan-2-ol-Solvate
GB9826180D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel process
GB9826171D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel compounds
GB9826242D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel process
GB9826178D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel process
GB9828767D0 (en) * 1998-12-29 1999-02-17 Smithkline Beecham Plc Novel process
IT1308629B1 (it) * 1999-02-23 2002-01-09 Recordati Chem Pharm Processo per la produzione di paroxetina.
ATE311883T1 (de) * 1999-03-12 2005-12-15 Aesica Pharmaceuticals Ltd Stabile pharmazeutische anwendungsform für paroxetin-anhydrat
GB9914583D0 (en) * 1999-06-22 1999-08-25 Smithkline Beecham Plc Novel process
GB9914585D0 (en) * 1999-06-22 1999-08-25 Smithkline Beecham Plc Novel process
SE9902550D0 (sv) * 1999-07-02 1999-07-02 Astra Ab New crystalline forms
GB9919001D0 (en) * 1999-08-12 1999-10-13 Smithkline Beecham Plc Novel process
GB9923439D0 (en) * 1999-10-04 1999-12-08 Smithkline Beecham Plc Novel process
GB9923446D0 (en) * 1999-10-04 1999-12-08 Smithkline Beecham Plc Novel process
GB9923445D0 (en) * 1999-10-04 1999-12-08 Smithkline Beecham Plc Novel process
HU226912B1 (en) * 2000-04-07 2010-03-01 Richter Gedeon Nyrt New paroxetin salt and medicament containing it
JPWO2002022609A1 (ja) * 2000-09-14 2004-01-22 旭硝子株式会社 実質的に有機溶媒を含まないパロキセチン塩類の製造方法
CA2476723A1 (en) * 2002-02-22 2003-09-04 Gideon Pilarski Preparation of paroxetine involving novel intermediates
JP2009516655A (ja) * 2005-11-22 2009-04-23 テバ ファーマシューティカル インダストリーズ リミティド シナカルセット塩酸塩の結晶形フォーム（Ｆｏｒｍ）、およびそれらの調製方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0223403A2 (en) * 1985-10-25 1987-05-27 Beecham Group Plc Piperidine derivative, its preparation, and its use as medicament

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
US5017585A (en) * 1986-11-03 1991-05-21 Novo Nordisk A/S Method of treating calcium overload
GB8626936D0 (en) * 1986-11-11 1986-12-10 Ferrosan As Treatment
DK716088D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Reduktion af piperidin-dion-derivater samt intermediat
DK715988D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Etherifikation og dealkylering af piperidin-derivater samt intermediater
AU658155B2 (en) * 1990-11-24 1995-04-06 Beecham Group Plc Use of paroxetine for the treatment of senile dementia, or anorexia
US5258517A (en) * 1992-08-06 1993-11-02 Sepracor, Inc. Method of preparing optically pure precursors of paroxetine
GB9325644D0 (en) * 1993-12-15 1994-02-16 Smithkline Beecham Plc Novel formulation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0223403A2 (en) * 1985-10-25 1987-05-27 Beecham Group Plc Piperidine derivative, its preparation, and its use as medicament

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BUXTON, P.C. et al. Solid-state forms of paroxetine hydrocholide. International Journal of Pharmaceutics, 42, (1988), pßginas 135-143 *

Also Published As

Publication number Publication date
CA2168829A1 (en) 1996-08-07
PT101827B (pt) 1997-08-29
CN1216055C (zh) 2005-08-24
ITMI960203A1 (it) 1997-08-05
RO112426B1 (ro) 1997-09-30
CN1289496C (zh) 2006-12-13
WO1996024595A1 (en) 1996-08-15
SI21923A (sl) 2006-06-30
CN1090187C (zh) 2002-09-04
SI21923B (sl) 2006-12-31
CN1310180A (zh) 2001-08-29
SE9600406D0 (sv) 1996-02-05
NO960472D0 (no) 1996-02-05
MC2411A1 (fr) 1996-12-02
MX9600484A (es) 1997-01-31
ES2114471B1 (es) 1999-08-16
FR2730232A1 (fr) 1996-08-09
DE69621777T2 (de) 2003-01-02
IT1289532B1 (it) 1998-10-15
AU701518C (en) 2006-12-07
AU4786496A (en) 1996-08-27
EP1136490A1 (en) 2001-09-26
MA23802A1 (fr) 1996-10-01
BR9600534A (pt) 1997-05-13
NO960472L (no) 1996-08-07
EP1378508A1 (en) 2004-01-07
AR001982A1 (es) 1998-01-07
KR960031409A (ko) 1996-09-17
SG43787A1 (en) 1997-11-14
IL117035A0 (en) 1996-09-12
SE521084C2 (sv) 2003-09-30
UA49796C2 (uk) 2002-10-15
IE80500B1 (en) 1998-08-12
FI20030370A7 (fi) 2003-03-12
NO970939L (no) 1996-08-07
NL1002248A1 (nl) 1996-08-06
DE69621777D1 (de) 2002-07-18
DE69631298T2 (de) 2004-11-18
FI960519A0 (fi) 1996-02-05
DK200100223A (es) 2001-02-12
CH689804A5 (de) 1999-11-30
EP1136490B1 (en) 2004-01-07
AT407528B (de) 2001-04-25
NO301009B3 (es) 2003-01-06
DE69631298D1 (de) 2004-02-12
EP0808314A1 (en) 1997-11-26
NO311519B1 (no) 2001-12-03
NL1002248C2 (nl) 1996-09-11
PL312646A1 (en) 1996-08-19
IL117035A (en) 2000-02-29
CA2210022A1 (en) 1996-08-07
CH689229A5 (de) 1998-12-31
TR199600096A2 (tr) 1996-08-21
ITMI960203A0 (es) 1996-02-05
LV11618B (en) 1997-04-20
HK59397A (en) 1997-05-16
SK283608B6 (sk) 2003-10-07
FR2730232B1 (fr) 1997-08-01
CA2210023A1 (en) 1996-08-07
CN1143643A (zh) 1997-02-26
PT101827A (pt) 1996-09-30
DK11996A (da) 1996-08-07
DZ1989A1 (fr) 2002-10-15
NO20015070L (no) 1996-08-07
ATA21096A (de) 2000-08-15
OA10261A (en) 1997-09-19
FI960519L (fi) 1996-08-07
JPH08245620A (ja) 1996-09-24
IE960104A1 (en) 1996-08-07
CA2211522C (en) 1999-12-07
BG100333A (bg) 1996-08-30
BG62967B1 (bg) 2000-12-29
FI20030370L (fi) 2003-03-12
CH688353A5 (de) 1997-08-15
CA2210022C (en) 2005-09-13
NO301009B1 (no) 1997-09-01
KR100289885B1 (ko) 2001-05-15
AU701518B2 (en) 1999-01-28
LU88711A1 (fr) 1996-08-23
NO20015070D0 (no) 2001-10-18
CZ297171B6 (cs) 2006-09-13
PL189247B1 (pl) 2005-07-29
HUP9600255A1 (en) 1997-03-28
CA2210023C (en) 1999-02-09
CZ32096A3 (en) 1996-08-14
JPH11228571A (ja) 1999-08-24
FI111544B (fi) 2003-08-15
SI9600036B (sl) 2006-12-31
NZ280943A (en) 1997-01-29
SI9600036A (en) 1996-10-31
DE19603797A1 (de) 1996-08-14
MX198371B (es) 2000-08-29
RU2125052C1 (ru) 1999-01-20
AR036856A2 (es) 2004-10-06
EP0808314B1 (en) 2002-06-12
LV11618A (lv) 1996-12-20
CN1636993A (zh) 2005-07-13
GR1002466B (el) 1996-11-06
DE19603797C2 (de) 1998-11-12
HU9600255D0 (en) 1996-03-28
AU4332896A (en) 1996-08-15
CA2168829C (en) 1997-12-16
SK14396A3 (en) 1996-11-06
SE9600406L (sv) 1996-08-07
MY132529A (en) 2007-10-31
CA2211522A1 (en) 1996-08-07
TW503238B (en) 2002-09-21
NO970939D0 (no) 1997-02-28
JP2915338B2 (ja) 1999-07-05
BE1009112A3 (fr) 1996-11-05
FI20030162L (fi) 2003-02-03
FI20030162A7 (fi) 2003-02-03

Similar Documents

Publication Publication Date Title
ES2114471A1 (es) Nuevos compuestos de paroxetina y procedimiento para su preparacion.
ES2132339T3 (es) Derivados sulfonato y carbamato de los 3-aroilbenzo(beta)tiofenos.
WO2002041883A3 (en) As-needed administration of tricyclic and other non-sri antidepressant drugs to treat premature ejaculation
CO4290424A1 (es) Pirazolopiridinas, pirrolopiridinas, composiciones farmaceu- ticas que las contienen y procedimientos para su administra- cion como antagonista del factor de liberacion de cortico- tropina
ECSP055684A (es) Antagonistas del receptor opiode
AR035158A1 (es) Inhibidores de recaptacion de norepinefrina altamente selectivos y metodo para usar los mismos
ES2164920T3 (es) Nuevos derivados heterociclicos y uso medicinal de los mismos.
ES2072323T3 (es) Compuestos de piperidina y su preparacion y empleo.
PE20020770A1 (es) Formulaciones de entecavir de dosis bajas y uso
AR003427A1 (es) Péptidos relacionados con dolastatina, procedimiento para prepararlos, composiciones farmacéuticas que los contienen y el uso de los mismos para la preparación de dichas composiciones farmacéuticas.
ES2065324T3 (es) N-(piridinil)-1h-indol-1-aminas, un procedimiento para su preparacion y su uso como medicamentos.
ES2160648T3 (es) Derivados de piridina.
ES2158778B1 (es) Compuestos de sales de paroxetina, su preparacion y uso, y composiciones farmaceuticas que los contienen.
ES2069755T3 (es) Preparacion de glutationa en aerosol y metodo para aumentar el nivel de glutationa en los pulmones.
ES2088388T3 (es) Composiciones de macrolido para el tratamiento de trastornos de movilidad gastrointestinal.
AR028624A1 (es) Heterociclilalquilaminas como antagonistas de receptores muscarinicos
AR009028A1 (es) Composiciones farmaceuticas, un procedimiento para preparar dichas composiciones y utilizacion de dichas composiciones en el tratamiento deenfermedades oftalmicas y metodos para tratar dichas enfermedades
UA45942A (uk) 1,3-оксатіолан, його похідні, спосіб (варіанти) його одержання та фармацевтична композиція
ES2084339T3 (es) Tetrahidropiridinas e hidroxipiperidinas sustituidas utiles como agentes para el sistema nervioso central.
ATE429925T1 (de) Methoden und pharmazeutische zusammensetzungen zur wundheilung
ES2150592T3 (es) Procedimiento para la preparacion de analogos de amidino-fenil-pirrolidin-beta-alanina urea.
ES2167021T3 (es) Derivados de acido 4-bifenil-4-hidroxibutirico sustituidos como inhibidores de metaloproteasa de matriz.
ES2109953T3 (es) 1,2,3,4-tetrahidrociclopent(b)indoles, 1,2,3,3a,4,8a-hexahidrociclopent(b)indoles sustituidos y compuestos relacionados, compuestos intermedios y un procedimiento para su preparacion y su uso como medicamentos.
AR021086A1 (es) Omega-amidas de n-arilsulfonil-aminoacidos, un procedimiento para su preparacion, medicamento, uso de dichos compuestos para la preparacion de un medicamento y procedimiento para la preparacion de un medicamento.
ES2039196T3 (es) Procedimiento para preparar 4-(1,2,5,6-tetrahidro-1-alquil-3-piridinil)-2-tiazolaminas y 4-(hexahidro-1-alquil-3-piridinil)-2-tiazolaminas.

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19980516

Kind code of ref document: A1

Effective date: 19980516

FC2A Grant refused

Effective date: 19990329

GD2A Contractual licences

Effective date: 20020215

GD2A Contractual licences

Effective date: 20030910

GD2A Contractual licences

Effective date: 20030910

FD2A Announcement of lapse in spain

Effective date: 20180806